Company news: Human Genome Sciences

Share this article:
Human Genome Sciences is laying off 150, mostly in manufacturing, due to slow demand for Benlysta, reports The Washington Post, which said CEO H. Thomas Watkins told investors last week that the company was "pleased" with sales for the first few quarters, which have built gradually, but that Wall Street has failed to understand the drug's trajectory and to price the company's stock accordingly.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions